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Summary
 
The migratory properties of memory T cells provide a model vector system for site-specific de-
livery of therapeutic transgene factors to autoimmune inflammatory lesions. Lymph node cells
 
from (SWR
 
3
 
SJL)F
 
1
 
 mice immunized with the p139–151 determinant of myelin proteolipid
protein (PLP) were transfected with a DNA construct that placed the anti-inflammatory cyto-
kine interleukin-10 (IL-10) cDNA under control of an antigen-inducible IL-2 promoter re-
gion. Isolated T cell clones demonstrated antigen-inducible expression of transgene IL-10 and
expressed cell surface markers consistent with the phenotype of normal memory T cells. Upon
adoptive transfer, transfected T cell clones were able to inhibit onset of experimental autoim-
mune encephalomyelitis (EAE) and to treat EAE animals therapeutically after onset of neuro-
logic signs. Semiquantitative immunocytochemistry showed a significant correlation between
decreased demyelination and treatment with the transfected T cells. Taken together, these data
indicate the autoreactive T cells can be genetically designed to produce therapeutic factors in
an antigen-inducible manner resulting in a decreased severity of clinical and histological au-
toimmune demyelinating disease.
 
E
 
xperimental autoimmune encephalomyelitis (EAE) is
an inflammatory neurologic disorder widely used as an
animal model for multiple sclerosis (MS) (1–4). EAE is me-
diated by CD4
 
1
 
 T cells of the Th1 phenotype (IL-2, IFN-
 
g
 
,
TNF-
 
b
 
) in response to encephalitogenic peptides of central
nervous system (CNS) myelin proteins. Recent studies have
indicated that CD4
 
1
 
 Th2 (IL-4, IL-5, IL-10) play an im-
munoregulatory role in inhibiting the disease process (5).
Thus, distinct native T cell subpopulations facilitate deliv-
ery of either proinflammatory or therapeutic factors to sites
of inflammation.
We hypothesized that the antigen specificity and migra-
tory properties of T cells may serve as an endogenous
model system for site-specific delivery of therapeutic trans-
gene factors during autoimmune disease. To test this hy-
pothesis, primed LN cells from (SWR
 
3
 
SJL)F
 
1
 
 (SWXJ) mice
immunized with the immunodominant p139–151 determi-
nant of myelin proteolipid protein (PLP) were transfected
with a transgene designed to provide expression of the anti-
inflammatory cytokine IL-10 cDNA gene under control of the
 
antigen-inducible IL-2 promoter (IL-2 Prom
 
®
 
IL-10cDNA).
IL-10 was chosen in the design of the transgene because in-
creased expression of IL-10 mRNA occurs in the CNS of
mice recovering from EAE and because of the ability of
IL-10 to inhibit macrophage-dependent stimulation of T cells
and production of proinflammatory cytokines (6–9). In ad-
dition, treatment with IL-10 has been shown to inhibit in-
duction of EAE in rats (10). The IL-2 promoter region was
selected for its ability to drive relatively high levels of ex-
pression of a reporter gene in Jurkat and EL4.E1 lymphoma
cell lines (11). Thus, our strategy was to modify T cells ge-
netically for delivering therapeutic factors in a nonconstitu-
tive, antigen-inducible manner during an autoimmune dis-
ease.
 
Materials and Methods
 
Transgene Construction and Transfection.
 
The mouse IL-2 pro-
moter region (
 
2
 
1890 to 
 
1
 
50) (a gift from Dr. E. Rothenberg)
was subcloned into a derivative of the pSI expression vector
(Promega, Madison, WI). The mouse IL-10 cDNA is from
pcD(SR
 
a
 
)-F115 (ATCC no. 68027; American Type Culture Col-
lection, Rockville, MD) (7). 7–10 d after immunization of SWXJ
mice with PLP 139–151, primed LN cells were reactivated in
vitro with PLP 139–151 (25 
 
m
 
g/ml). After 96 h, activated blast
cells were enriched by Ficoll centrifugation and transfected using
polybrene/DMSO-assisted gene transfer (12, 13). Cells were sus-
pended in flat-bottomed 24-well plates at 3 
 
3
 
 10
 
6
 
 cells/ml in pre-
 
warmed transfection media consisting of 10 
 
m
 
g/ml IL-2Prom
 
®
 
IL-10cDNA transgene, 1.0 
 
m
 
g/ml of pSV2
 
neo
 
 plasmid (ATCC no.
37149), and 20 
 
m
 
g/ml polybrene (Sigma, St. Louis, MO) in
DMEM (GIBCO BRL, Gaithersburg, MD). After 6 h, the cells
were shocked with prewarmed 30% DMSO in DMEM, washed,
and cultured at 1 
 
3
 
 10
 
6
 
 cells/ml in 24-well plates in a total volume
of 2.0 ml/well with 50 IU/ml mouse IL-2 (PharMingen, San Di-
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ego, CA) and 5 
 
3
 
 10
 
6
 
 x-irradiated (2 
 
3
 
 10
 
3
 
 rads) syngeneic sple-
nocytes/well. After 48 h, cultures were treated with 1.0 mg/ml
geneticin (Sigma Chem. Co., St. Louis, MO; 700 
 
m
 
g/ml active
substance) and 50 IU/ml mouse IL-2. Cells were harvested at 6 d,
reactivated with peptide plus feeders in 24-well plates at 5 
 
3
 
 10
 
5
 
cells/well, and expanded conventionally by alternate activation/
rest cycles with antigen/IL-2. Cells were cloned at 0.3–1.0 cell/
well by limiting dilution and selection with antigen and IL-2.
Proliferation assays were performed in flat-bottomed 96-well mi-
crotiter plates with 5.0 
 
3
 
 10
 
4
 
 T10.11 cells/well and 5.0 
 
3
 
 10
 
5
 
x-irradiated SWXJ splenocytes/well. ELISAs were performed
with purified anti-mouse cytokine capture–detection antibody
pairs (PharMingen, San Diego, CA) on 48-h supernatants from
bulk cultures. The capture–detection antibody pairs included the
following: anti-mouse IFN-
 
g
 
 (R4-6A2 and biotin–XMG1.2),
anti-mouse IL-4 (BVD4-1D11 and biotin–BVD6-24G2), anti-
mouse TNF-
 
a
 
 (MP6-XT22 and biotin–MP6-XT3), and anti-
mouse IL-10 (JES5-2A5 and biotin–SXC-1). Standard values
were plotted as absorbance at 405 nm OD versus concentrations
of recombinant cytokine standards (PharMingen, San Diego,
CA). Unknown cytokine concentrations were determined as val-
ues within the linear part of the standard curve.
 
RNase Protection Assay (RPA).
 
RNA was isolated using either
guanidine isothiocyanate and CsCl as described previously or with
the TRIZOL
 
Ô
 
 reagent (GIBCO BRL, Gaithersburg, MD) fol-
lowing the instructions of the manufacturer (14–16). An Asp 700
fragment was subcloned from the IL-2Prom
 
®
 
IL-10cDNA trans-
gene that included the 3
 
9
 
 end of the IL-2 promoter region, in-
tronic sequences, vector sequences, and the 5
 
9
 
 end of the mouse
IL-10  cDNA. This construct was linearized with EcoRI and
 
a
 
-[
 
32
 
P]UTP-labeled RNA probe synthesized using the Bluescript
T
 
3
 
 promoter. RPA was performed using the RNase Protection
Assay (RPA) II system (Ambion, Austin, TX). The resulting di-
gestion products were separated on 5% Hydrolink P600 gels (J.T.
Baker, Phillipsburg, NJ), dried, and exposed to Biomax MR film
(Eastman Kodak, Rochester, NY). The RNA expression levels
were quantified using a PhosphoImager (Molecular Dynamics,
Sunnyvale, CA).
 
Active EAE Induction.
 
EAE was induced as previously de-
scribed (17) by subcutaneous immunization of SWXJ mice with
the immunodominant PLP 139–151 peptide in an emulsion of
equal volumes of water and CFA (Difco, Detroit, MI). On days 0
and 3, each mouse also received intravenously 0.6 
 
3
 
 10
 
10
 
 
 
Borde-
tella pertussis
 
 bacilli (Michigan Department of Public Health). All
mice were weighed and examined daily for neurologic signs in a
blinded manner.
 
Histologic Analysis and Quantification.
 
Spinal cords were fixed
in 10% phosphate-buffered formalin, and paraffin-embedded tissue
sections were cut (10 
 
m
 
m each) for immunostaining. Sections
were pretreated with 0.04% OsO
 
4
 
 and 1% H
 
2
 
O
 
2
 
 in 10% Triton
(Electron Microscopy Sciences, Fort Washington, PA) and blocked
with 5% normal goat serum (Vector, Burlingame, CA) and 5%
nonfat dehydrated milk for 60 min. Sections were treated sequen-
tially with PLP monoclonal IgG
 
2a
 
 antibody (Harlan) at a 1
 
;
 
200
dilution for 14 h at 4
 
8
 
C, biotinylated goat anti–mouse IgG
 
2a
 
(Southern Biotechnology, Birmingham, AL) at a 1
 
;
 
500 dilution
for 30 min at 22
 
8
 
C, and avidin–peroxidase complex (Vector,
Burlingame, CA) for 1 h at 1
 
;
 
1,000 dilution. Sections were then
treated with diaminobenzidine and 0.01% H
 
2
 
O
 
2
 
 for 8 min, 0.04%
OsO
 
4
 
 for 30 s and washed in PBS. Images were digitized using
the Oncor Imaging System (Gaithersburg, MD) at 640 
 
3
 
 480
pixel resolution. All images were normalized by adjusting back-
ground gray matter stain to the same mean intensity value using
Adobe Photoshop (Adobe Systems, Mountain View, CA). At
least 12 images per animal were analyzed. The dorsal columns
were outlined and the percentage of pixels representing the dark-
est 25% of stain was determined using NIH Image software.
 
Statistical Analysis.
 
The two-sided Student’s 
 
t
 
 test was used
for determining differences in mean clinical scores of treated and
control EAE mice as well as differences in percent immunostain-
ing between control and experimental spinal cords.
 
Results and Discussion
 
A transgene construct (IL-2Prom
 
®
 
IL-10cDNA) was de-
signed by fusing a mouse IL-2 promoter region (
 
2
 
1890 to
 
1
 
50) to the mouse IL-10 cDNA (Fig. 1 
 
a
 
). The transgene
construct also contained intron splices sites and the SV40
late polyadenylation signal region to ensure high levels of
IL-10 expression. In this way, T cells were designed so that
an IL-2 promoter region would regulate synthesis of IL-10
in an antigen-inducible, nonconstitutive manner.
T cells were prepared by in vitro activation of primed
LN cells from SWXJ mice immunized with the PLP 139–
151 peptide. In our hands, this method consistently pro-
duces encephalitogenic T cells capable of passively transfer-
ring EAE into naive animals.
Peptide-activated T cells were transfected with both the
IL-2Prom
 
®
 
IL-10cDNA transgene and the selectable marker
plasmid, pSV2
 
neo
 
. 
 
Neo
 
-resistant T cells were expanded, and
T cell clones were isolated and analyzed. Clone T10.11 was
selected for further study because of its marked antigen
Figure 1. The IL-2Prom®IL-10cDNA transgene and characteriza-
tion of transfected T cells. (a) Schematic representation of the transgene
IL-2Prom®IL-10cDNA showing IL-2 promoter region, IL-10 cDNA,
and SV40 polyadenylation signals. Intron sequences are labeled and vector
sequences are indicated by solid lines. (b) Proliferative responses of T cell
clone T10.11 after peptide activation. 5 3 105 clone cells were stimulated
(25 mg/ml) with the immunodominant PLP 139–151 HSLGKWLGHP-
DKF, and with PLP 104–117 KTTICGKGLSATVT, a noncross-reacting
control encephalitogen for SWXJ mice (17, 26). The data show the stim-
ulation index (cpm test/cpm background) of [3H]thymidine incorporation by
T10.11 clone cells 48 h after activation with peptide. Error bars show 6
SD. (c) Cytokine levels were measured on 48-h supernatants from clone
T10.11 cells cultured without antigen (resting cells) and after activation
with PLP 139–151. Cytokine concentrations were normalized to total
cell numbers. 
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Table 1.
 
Flow Cytometry Analysis of IL-2Prom
 
®
 
IL-10cDNA–transfected T Cells
 
*
 
Cell surface antigen
Percentage of positive staining cells
Normal
p139–151-specific
T cell line
Transfected
p139–151-specific
T cell line
Transfected
p139–151-specific
T10.11 T cell clone
CD3 92.3 91.7 95.1
CD4 94.6 93.0 99.6
CD8 0.8 2.9 0.4
TCR 
 
ab
 
95.5 93.6 98.6
TCR-V
 
b
 
14 14.9 ND 99.5
CD25 (IL-2R
 
a
 
) 68.8 65.6 ND
CD44 (Pgp-1) 95.1 93.7 92.4
CD49d (VLA-4) 45.3 42.2 41.2
CD62L (
 
L
 
-selectin) ND 20.6 19.2
 
*
 
Two-color flow cytometry analysis of PLP 139–151-activated fixed T cells was performed with PE-conjugated rat mAb to mouse CD3 or CD4
(GIBCO BRL) and FITC-conjugated mAb to either TCR 
 
ab
 
 chains (TCR 
 
ab
 
), CD25 (IL-2R 
 
a
 
 chain), CD44 (Pgp-1, CD49d (VLA-4; 
 
a
 
4
 
b
 
1
 
 in-
tegrin), or CD62L (
 
L
 
-selectin) (PharMingen). Single-color analysis with FITC-conjugated antibodies (PharMingen) was used for determining TCR-V
 
b
 
utilization. Isotype-matched FITC- and PE-conjugated mAb were used as controls. Data were collected on 20,000 events with a FACScan
 
Ò
 
 flow cy-
tometer. Analysis was performed on the gated lymphoblast population using Cellquest software (Becton Dickinson).
specificity (Fig. 1 b) and its ability to generate a substantial
increase in IL-10 cytokine production upon activation with
antigen (Fig. 1 c).
An RPA was used to differentiate between IL-2Prom®
IL-10cDNA transgene and endogenous IL-10 gene expres-
sion. RNA from resting and antigen-activated T10.11 cells
was hybridized to an RNA probe prepared from the 59 end
of the IL-10 cDNA that incorporated transcribed-transgene
vector sequences (Fig. 2 a). Two RNA transcripts were
protected from activated T10.11 cells, indicating that both
endogenous and transgene IL-10 expression were induced
after stimulation with antigen (Fig. 2 b). Transgene expres-
sion represented 40% of the total IL-10 mRNA, and in-
creased 7.5-fold after activation with PLP 139–151 compared
with a 6.1-fold antigen-induced increase in endogenous
IL-10 mRNA. Thus, antigen-inducible expression of trans-
gene IL-10 mRNA occurred concomitant with endogenous
IL-10 gene expression.
Flow cytometry analysis showed that transfected T10.11
cells expressed a cell surface phenotype consistent with
normal memory T cells. After antigen stimulation, T10.11
cells were CD31, CD41, CD8dim, TCRab1, Vb141 T cells
with high level expression of the activation antigens CD44
(Pgp-1), CD49d (VLA-4), and CD25 (IL-2R) and low
Figure 2. Detection of transgene IL-10 mRNA in T10.11 clone cells.
An RNase protection assay (RPA) was used for distinguishing endoge-
nous and transgene mRNA. (a) The DNA construct used to generate the
RNA probe for measuring IL-10 expression. The RNA probe is repre-
sented by an arrow and protected RNase digestion products are shown.
(b) RNase-digestion products after hybridization to 32P-labeled RNA probe.
Lane 1, yeast RNA; lane 2, RNA from rested T10.11 clone cell 11 d after
activation with PLP 139–151; lane 3, RNA from activated T10.11 clone
cells 48 h after activation with PLP 139–151; lane 4, spleen RNA. 
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level expression of CD62L (
 
l
 
-selectin), a marker for native
T cells (Table 1).
The development of EAE in SWXJ mice is characterized
by acute onset of paralytic disease within 3 wk after immu-
nization with PLP 139–151. Mice typically recover and
undergo a relapsing–remitting disease course with progres-
sion to chronic disability accompanied by perivascular mono-
nuclear infiltrates and demyelination in CNS white matter.
To evaluate the therapeutic potential of IL-2Prom
 
®
 
IL-10
cDNA transfected T cells, T10.11 clone cells were adop-
tively transferred into SWXJ mice before the anticipated
onset of PLP 139–151-induced EAE as well as after onset
of clinical disease. Transfer of T10.11 T cells was found to
be effective in inhibiting the onset of EAE (Fig. 3 
 
a
 
) and in
therapeutically altering the course of disease when trans-
ferred after initiation of neurologic signs (Fig. 3 
 
b
 
). The in-
hibitory effect of clone T10.11 was similarly mimicked by
transfer of PLP 139–151-specific T cell lines also trans-
fected with the IL-2Prom
 
®
 
IL-10cDNA construct (Fig. 3
 
a
 
). In contrast, transfer of either normal splenocytes or IL-2
Prom
 
®
 
IL-10cDNA–transfected T cell lines specific for the
irrelevant non-CNS antigen, KLH, produced no sustained
therapeutic effect on either EAE onset or progression.
KLH-specific transfected T cell lines showed antigen-
inducible production of IL-10 in a manner similar to that
observed in transfected autoreactive T cells (data not
shown).
To determine the histologic effects after adoptive transfer
of transfected T cells, spinal cords from mice receiving ei-
ther IL-2Prom
 
®
 
IL-10cDNA–transfected T cells (Fig. 4 
 
b
 
) or
normal splenocytes (Fig. 4 
 
a
 
) just before EAE onset were
stained immunocytochemically for PLP, and demyelination
was quantified by measuring the mean intensity of dorsal
column PLP staining. Adoptive transfer of IL-2Prom
 
®
 
IL-10
cDNA–transfected T cells just before EAE onset resulted in
a significant (
 
P
 
 
 
5
 
 0.02) mean decrease of 12.2% in CNS
demyelination compared with EAE mice receiving normal
splenocytes.
Ectopic expression of anti-inflammatory cytokines has
produced conflicting results in the treatment of immune-
mediated inflammation. Allograft survival is prolonged after
retroviral-mediated transfection of murine cardiac trans-
plants with viral IL-10 (18), and onset of collagen-induced
arthritis is delayed in DBA/1 mice injected with Chinese
hamster ovary (CHO) fibroblasts transfected with IL-4 or
IL-13 (19). In contrast, expression of transgene IL-10 in
pancreatic islet 
 
b
 
 cells actually accelerates the development
of autoimmune diabetes in nonobese diabetic (NOD) mice
(20). Controversy is also apparent in reports which show
efficacy in treating ongoing EAE by transfer of traditional
Th2 T cell clones cells (5), but only modest therapeutic ef-
fect when Th2 T cells are transferred before disease induc-
tion (21). However, it is clear that proliferation of enceph-
alitogenic Th1 T cells can be inhibited by IL-10, but not
Figure 3. Inhibition and treatment of EAE
with autoreactive T cells transfected with IL-2
Prom®IL-10cDNA. (a) Inhibition of EAE on-
set after adoptive transfer of 1 3 107 T10.11
clone cells or IL-2Prom®IL-10cDNA–trans-
fected T cell lines specific for PLP 139–151.
Recipient SWXJ mice were immunized for
EAE induction with PLP 139–151 18 d before
tail vein injection with antigen-activated T
cells. Mice showed no signs of EAE before
transfer. No therapeutic effect occurred in mice
receiving 1 3 107 normal splenocytes or acti-
vated IL-2Prom®IL-10cDNA–transfected cells
specific for the irrelevant control antigen, key-
hole limpet hemocyanin (KLH). (b) Therapeu-
tic treatment after EAE onset by transfer with
IL-2Prom®IL-10cDNA–transfected T10.11
clone cells. 3 d after EAE onset, mice were in-
jected intravenously with 1 3 107 activated T cells. No therapeutic effect was observed in mice transferred with nonactivated normal splenocytes or with
activated transfected T cells specific for KLH. All mice were weighed and examined daily for neurologic signs in a blinded manner according to the fol-
lowing criteria. Clinical scores are 0, no disease; 1, decreased tail tone or slightly clumsy gait; 2, tail atony and/or moderately clumsy gait and/or poor
righting ability; 3, limb weakness; 4, limb paralysis; 5, moribund state. Error bars show 6 SEM.
Figure 4. Histologic analysis of CNS tissue after adoptive transfer of
transfected T cells. The extent of demyelination was measured by immu-
nocytochemical staining for PLP. (a) Representative section showing de-
myelination (arrow) in the spinal cord dorsal column of SWXJ control
mouse adoptively transferred with normal splenocytes before EAE onset.
(b) Representative section showing uniform distribution of PLP immu-
nostaining in the spinal cord dorsal column of SWXJ mouse adoptively
transferred before EAE onset with PLP 139–151-specific T cells trans-
fected with the IL-2Prom®IL-10cDNA construct. Closed Bar, 50 mm.
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by IL-4 secreted from Th2 T cells having identical antigen
specificity (22). It is worth noting that treatment with re-
combinant IL-10 has also produced conflicting outcomes re-
sulting in either exacerbation (23) or amelioration (10) of EAE.
In a recent report related to the present study, Shaw et al.
(24) demonstrated a delay in EAE onset and a decrease in
disease severity after transfer of myelin basic protein–specific
T cell hybridomas that had been retrovirally transduced
with IL-4. However, in contrast with the present study,
expression of the IL-4 transgene was constitutive, and all of
the mice eventually died from overgrowth of the hybridoma
tumor cells.
The results of the present study show that transfected an-
tigen-specific T cells are effective when used either to in-
hibit onset of EAE or to treat ongoing disease. In a broader
sense, our data indicate that T cells can be genetically al-
tered with nonviral vectors to provide antigen-inducible
production of therapeutic transgene proteins while main-
taining an otherwise normal memory T cell phenotype.
Thus, genetic modification of T cells may provide a means
for both identifying and delivering therapeutic transgene
factors capable of modulating inflammation. Moreover, it
may be possible to use transgene-altered T cells for deliver-
ing appropriate growth factors for tissue repair, particularly
in light of recent experiments showing that T cells consti-
tutively expressing nerve growth factor are less capable of
mediating experimental autoimmune neuritis (25). Insights
gained from genetic modification of T cells in the EAE an-
imal model may provide a rational basis for treating the au-
toimmune demyelination widely believed to be responsible
for chronic progression of MS.
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